← Back to screener

Immunome Inc. IMNM

Rank #2467 · Nasdaq · $2.1B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
15.6
P/E
-7.0
P/B
17.20
ROE
-244.4%
Op. Margin
-3382.4%
Debt Ratio
49%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -7.0x, P/B 17.20x. Ranks in the top 87% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -244.4%. Ranks in the top 98% of the universe.

Safety ★★★★☆
Good

Debt ratio 49%. Ranks in the top 23% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 35.5% year over year. Ranks in the top 96% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020–$-0.0B$-0.0B$-0.0B–-7
2021–$-0.0B$-0.0B$-0.0B–-9
2022–$-0.0B$-0.0B$0.0B–24
2023$0.0B$-0.0B$-0.0B$0.0B-263.215
2024$0.0B$-0.1B$-0.1B$0.0B-781.4172
2025$0.0B$-0.3B$-0.3B$0.1B-3382.449

← See the full screener